SML3804

PMX205 trifluoroacetate

≥98% (HPLC)

• Synonim(y): Hydrocinnamate (HC)-[OP(D-Cha)WR] trifluoroacetate, (5→1)-lactam-N2-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginine trifluoroacetate, HC-[OP(D-Cha)WR] trifluoroacetate, HC-[Orn-Pro-dCha-Trp-Arg] trifluoroacetate, Hydrocinnamate-(L-ornithine-proline-D-cyclohexylalanine-tryptophan-arginine) trifluoroacetate;, Hydrocinnamate-(OPdChaWR) trifluoroacetate, Hydrocinnamate-[OP(D-Cha)WR] trifluoroacetate, PMX 205 trifluoroacetate, PMX-205 trifluoroacetate, c[Arg-Trp-D-Cha-Pro-Orn]-Hca trifluoroacetat
• Wzór empiryczny (zapis Hilla): C₄₅H₆₂N₁₀O₆ · xC₂HF₃O₂
• Masa cząsteczkowa: 839.04 (free base basis)
• UNSPSC Code: 51111800
• NACRES: NA.21
• MDL number: MFCD31735786
• Assay: ≥98% (HPLC)
• Form: (Powder or Lyophilized powder or film)
• Storage condition: desiccated

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: (Powder or Lyophilized powder or film)
• storage condition: desiccated
• color: white to off-white
• storage temp.: -10 to -25°C
• SMILES string: N21[C@@H](CCC2)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCCC[C@@H](C1=O)NC(=O)CCc6ccccc6)CCCNC(=N)N)Cc4c5c([nH]c4)cccc5)CC3CCCCC3
• InChI: 1S/C45H62N10O6/c46-45(47)49-24-9-18-34-40(57)48-23-10-19-35(51-39(56)22-21-29-12-3-1-4-13-29)44(61)55-25-11-20-38(55)43(60)54-36(26-30-14-5-2-6-15-30)41(58)53-37(42(59)52-34)27-31-28-50-33-17-8-7-16-32(31)33/h1,3-4,7-8,12-13,16-17,28,30,34-38,50H,2,5-6,9-
• InChI key: VATFHFJULBPYLM-ILOBPARPSA-N

Opis

Biochem/physiol Actions

Blood-brain barrier-permeable and orally active C5aR1 antagonist with 10- to 30-times higher in vivo efficacy than PMX53 in a rat colitis model.

PMX205 is a blood-brain barrier (BBB)-permeable and orally active cyclic hexapeptide that acts as a high-affinity and potent antagonist against complement C5a receptor C5aR1. Unlike its structural analog PMX53, PMX205 is resistant to intestinal metabolism and shows 10-30-times higher in vivo efficacy when administered orally (mortality rate = 1/9 with 0.1 mg/kg/day PMX205 vs. 2/10 with 1 mg/kg/day PMX53 in a rat colitis model) despite similar in vitro potency (PMX205/PMX53 pIC50 = 6.50/6.38 against 50 pM C5a by competitive binding, 9.03/8.24 against C5a-induced human PMN MPO release). PMX205 shows in vivo efficacy in animal models of AD (3-6 mg/kg/day p.o., mice), ALS (1 mg/kg/day p.o., rats), and HD (10 mg/kg/day p.o., rats).

Disclaimer

Hygroscopic

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable